Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum / Q000191:economics / Q000627:therapeutic use; D000077552:Basiliximab; D003362:Cost-Benefit Analysis; D000077561:Daclizumab; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000191:economics* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000191:economics*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D006435:Renal Dialysis / Q000191:economics; D012189:Retrospective Studies; D016896:Treatment Outcome